Cataract surgery patients treated with branded nepafenac topical eye drops reported better objective and subjective outcomes compared with patients treated with generic ketorolac, according to a study.“This study proves what many clinicians have observ…
Author: Healio ophthalmology
Glaukos targets global glaucoma market
Glaukos is aiming to tackle the glaucoma market with micro-devices that include the iStent and iDose devices, CEO Tom Burns said at the 37th annual J.P. Morgan Healthcare Conference in San Francisco.“Our mission is aspirational,” he said. “As a company…
OSN’s top stories of the week
Here are the top five stories on Healio.com/OSN last week: Bimatoprost sustained-release implant reduces IOP in phase 3 studyA bimatoprost sustained-release implant reduced IOP by approximately 30% over 12 weeks in a second phase 3 study. Read more. Ne…
Read OSN’s Jan. 10 publication exclusives online
The cover story in the Jan. 10, 2019, issue of Ocular Surgery News focuses on new glaucoma therapies and delivery systems.Here are some of the issue’s publication exclusives: Cover StoryNew pharmacotherapies and delivery systems broaden glaucoma landsc…
One in four anti-VEGF therapy patients with DME lost to follow-up
A quarter of patients with diabetic macular edema who received an anti-VEGF injection to treat nonproliferative diabetic retinopathy did not return for a follow-up visit within the ensuing 12 months, according to a study.The retrospective cohort study …
VIDEO: The evolution of toric IOL alignment
NEW YORK — From OSN New York 2018, Mitchell A. Jackson, MD, founder and CEO of Jacksoneye in Lake Villa, Illinois, gives his presentation on the evolution of toric IOL alignment or “show me the nubs, the new gold standard.”
Lombart, Marco form Advancing Eyecare Holdings
Atlantic Street Capital announced that it will form Advancing Eyecare Holdings with a partnership between Marco Ophthalmic and Atlantic’s portfolio company, Lombart Instrument.The transaction is expected to be completed in the first quarter of 2019 and…
VIDEO: What’s new in IOL calculations
NEW YORK — From OSN New York 2018, Mitchell P. Weikert, MD, associate professor at the Cullen Eye Institute, Baylor College of Medicine, gives his presentation on the latest in how to perform IOL calculations for cataract surgery.
Price hikes on older, brand-name drugs share blame for surging drug costs
The pharmaceutical industry, in recent years, has been marked by a cycle of outrage from patient groups, insurers and politicians each time a particularly expensive new drug hits the market. The considerable ticket price attached to blockbuster newcome…
Ocular Therapeutix submits supplemental NDA for Dextenza
A supplemental new drug application for Dextenza has been submitted to the FDA to expand its indication to include the treatment of ocular inflammation after ophthalmic surgery, Ocular Therapeutix announced in a press release.Dextenza (dexamethasone op…
VIDEO: State of the art of intracameral antibiotics and steroids
NEW YORK — From OSN New York 2018, Keith Walter, MD, professor of ophthalmology and director of refractive surgery at Wake Forest University, gives his presentation on the state of the art of intracameral antibiotics and steroids for “drop-free” catara…
Allergan reports continued focus on eye care business
Allergan’s commitment to its eye care business includes advancing new products for both the front and back of the eye, CEO Brent Saunders said at the 37th annual J.P. Morgan Healthcare Conference in San Francisco.The company’s business plan included a …
VIDEO: Software and apps to improve today’s cataract surgeon
NEW YORK — From OSN New York 2018, Tal Raviv, MD, founder and medical director of Eye Center of New York, gives his presentation on different software and apps that will help cataract surgeons improve their practice.
Optometry must follow neurology’s standard of care in retinal artery obstruction
Neurologists consider an acute retinal artery obstruction a true medical emergency and classify it as a stroke.Scott C. Richards, MD, suggests optometrists implement a “major shift” in the referral pattern for retinal artery obstructions by taking a pa…
Large data set correlates cholesterol levels with AMD
HDL cholesterol and triglycerides have, respectively, a positive and negative association with increased risk for age-related macular degeneration, particularly in the early stages, according to a study.Researchers analyzed the correlation between circ…
Spark leverages Luxturna success to move gene therapies forward
Spark Therapeutics’ success with Luxturna is spurring the company to develop more gene therapies for other genetic diseases, Jeffrey D. Marrazzo, the company’s co-founder and CEO, said at the 37th annual J.P. Morgan Healthcare Conference in San Francis…
VIDEO: Leber hereditary optic neuropathy gene therapy shows positive results
CHICAGO — Mark L. Moster, MD, of Wills Eye Hospital, discusses results of the REVERSE clinical trial, which is evaluating the efficacy of GS010 (GenSight Biologics) to treat Leber hereditary optic neuropathy, at the American Academy of Ophthalmology me…
Ciliary neurotrophic factor may benefit patients with macular telangiectasia type 2
Intravitreal sustained delivery of human ciliary neurotrophic factor showed efficacy in slowing the progression of retinal degeneration in patients with macular telangiectasia type 2, a condition with no known effective therapy.Ciliary neurotrophic fac…
Takeda completes Shire acquisition
Takeda Pharmaceutical has completed its acquisition of Shire, 8 months after the deal was announced, according to a press release.The deal was approved by 89.1% of Takeda’s shareholders and 99.8% of Shire’s shareholders, the release said.“We are deligh…
ProQR to begin phase 2/3 trial of treatment for Leber’s congenital amaurosis 10
ProQR Therapeutics and the FDA have reached an agreement regarding the design of the phase 2/3 ILLUMINATE trial of the company’s RNA-based oligonucleotide treatment candidate for Leber’s congenital amaurosis 10, according to a press release.The double-…